Furthermore, the reduced expression of dystrophin in the sarcolemma could be confirmed by immunohistochemistry, which let us hypothesize that observed abnormalities may have been caused by a dystrophinopathy. This evidence concerns the gene DMD and neuromuscular disease caused by qualitative or quantitative defects of dystrophin.